33rd week of 2022 patent applcation highlights part 26 |
Patent application number | Title | Published |
20220259267 | Inhibition Of TCR Signaling With Peptide Variants - The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCRαβ-CD3δε-CD3γε-ζζ signaling complex. Yet more specifically, the peptides act on the TCRα/CD3δε/ζζ signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions. Specifically, the compositions are useful in the treatment and/or prevention of a disease or condition where T cells are involved or recruited. The compositions of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices). | 2022-08-18 |
20220259268 | ADHESIVE PROTEIN - The present invention provides a novel polypeptide. The polypeptide found by the inventors of the present invention does not have self-cohesive properties and has adhesive properties. The adhesive polypeptide according to the present invention comprises a fragment of the amino acid sequence represented by SEQ ID NO: 1. The adhesive polypeptide according to a specific embodiment of the present invention includes, from among the amino acid sequence represented by SEQ ID NO: 1, amino acids at positions 22-50 and positions 161-175, and also includes, from among amino acids at positions 2847-3093, deletion of a region required to impart self-cohesive properties. | 2022-08-18 |
20220259269 | EVOLVED BOTULINUM NEUROTOXINS AND USES THEREOF - The disclosure provides amino acid sequence variants of Botulinum neurotoxin F (BoNT F) proteases that cleave SNARE proteins (e.g., VAMP1, VAMP7, etc.) and methods of evolving the same. In some embodiments, proteases described by the disclosure are useful for cleaving proteins found in a cell, that is in an intracellular environment. In some embodiments, proteases described by the disclosure are useful for treating diseases associated with increased or aberrant VAMP7 expression or activity, for example, cancer, transplantation rejection, graft-versus-host disease, and neurological disorders. Some aspects of this disclosure provide methods for generating BoNT protease variants by continuous directed evolution. | 2022-08-18 |
20220259270 | MODIFIED TRICHODERMA FUNGAL STRAIN FOR THE PRODUCTION OF AN ENZYME COCKTAIL - The present invention relates to a novel strain of | 2022-08-18 |
20220259271 | HIGH CONTRAST PHOTOCONVERTIBLE FLUORESCENT PROTEINS AND METHODS OF USE - Disclosed herein, are photoconvertible fluorescent proteins or analogs thereof, and in particular, green-to-red photoconvertible fluorescent proteins or analogs thereof of the EosFP family; and compositions comprising the same and methods for analyzing a physiologically active substance in a cell wherein the fluorescent proteins are expressed in the cell. | 2022-08-18 |
20220259272 | PHOTOACTIVE COMPOSITIONS FOR THERAPUETIC AGENT DELIVERY - In one aspect, photoactive compositions are described herein for targeted or selective delivery of therapeutic agents to diseased tissue and/or diseased sites within a patient. A photoactive composition comprises a membrane-based carrier and a photoactivated lytic component coupled to the membrane-based carrier, the photoactivated lytic component comprising a lysing agent and photolabile lytic blocking agent. | 2022-08-18 |
20220259273 | COMPOSITIONS AND METHODS FOR TREATING PROTEIN AGGREGATION-ASSOCIATED DISEASES - Compositions and methods for treating aggregation-associated diseases are disclosed. In particular, compositions comprising the nascent polypeptide-associated complex (NAC) and the apical domain of CCT1 as well as peptide fragments thereof and fusion proteins containing NAC and CCT1 peptides can be used to suppress pathological protein aggregation and are useful for treatment of diseases associated with polyQ aggregation, amyloid beta aggregation, and alpha-synuclein aggregation. | 2022-08-18 |
20220259274 | METHODS AND COMPOSITIONS RELATED TO RECOMBINANT NEIL2 - Certain embodiments are directed to NEIL2 compositions and method of using NEIL2 composition to treat subjects in need of such treatment. | 2022-08-18 |
20220259275 | NOVEL PEPTOID BLOCKING O-GlcNAcylated NF-kappaB c-Rel - The present disclosure relates to peptoids for inhibiting O-GlcNAcylated proteins, and in particular, the c-Rel peptide of NF-kappaB. The compounds can be used in the prevention or treatment of diseases of conditions having elevated levels of O-GlcNAcylation, such as autoimmune diseases, conditions that are related to hyperglycemia, or cancers. | 2022-08-18 |
20220259276 | VGLL4 WITH UCP-1 CIS-REGULATORY ELEMENT AND METHOD OF USE THEREOF - Provided is a polynucleotide, including a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein, wherein the cis-regulatory element includes an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter. Also provided is a viral vector including said polynucleotide. Also provided is a method of transfecting a cell or a subject with said polynucleotide or said viral vector. | 2022-08-18 |
20220259277 | METHOD FOR MANUFACTURING A STABLE EMULSION FOR PEPTIDE DELIVERY - The present invention pertains to a method for manufacturing a ready-to-use peptide emulsion on the industrial scale, comprising the step of emulsifying a suspension of at least two peptides under low shear conditions with at least one adjuvant. It is also directed to a ready-to-use emulsion obtainable according to this method. This invention allows the delivery of a scalable emulsion of peptides which preserves their integrity and fulfills the requirements needed for a pharmaceutical sterile product. | 2022-08-18 |
20220259278 | NOVEL FUSION PROTEIN AND USE OF SAME - The present invention relates to a novel fusion protein and use thereof, and more particularly, to a fusion protein specifically binds to CD154 comprising Fab or scFv specifically binding to CD154 Fc regions, wherein the Fc region is a modified Fc region which is modified so as not to bind to an Fc gamma receptor. | 2022-08-18 |
20220259279 | ALGINATE-BASED MICROCAPSULATION FOR THE DELIVERY OF ALPHA-CGRP IN CARDIOVASCULAR DISEASES - Methods and systems for delivering a very potent vasodilator that has the ability to treat and prevent heart failure including delivering microcapsules containing α-CGRP, which show no toxicity and lowers blood pressure similar to the native peptide, where this new compound could greatly enhance the lifespan of patients suffering from heart failure. | 2022-08-18 |
20220259280 | BACILLUS THURINGIENSIS TOXIN RECEPTORS AND USES THEREOF - The invention relates to identification and characterization of recombinant DNA and polypeptides for specific Bt toxin receptors. In particular, the Bi toxin receptors of the invention include those derived from the Lepidopteran super family including the species | 2022-08-18 |
20220259281 | CHIMERIC PROTEIN EXPRESSING T-CELLS - The present invention relates to, inter alia, compositions and methods, including engineered T cells that express chimeric antigen receptors and heterologous chimeric proteins that find use in the treatment of cancer. | 2022-08-18 |
20220259282 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN FELINES AND METHODS OF USE - Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a feline and methods of their use. The compositions involve variant feline IgG Fc regions. | 2022-08-18 |
20220259283 | SORCS2 CRYSTAL STRUCTURE AND USES THEREOF - The present invention relates to a SorCS2 crystal structure, the atomic coordinates obtained by X-ray crystallography of same, and their use in molecular modelling. The invention further relates to methods of growing crystals of SorCS2. Furthermore, the invention relates to peptides capable of binding to SorCS2, as well as their use as medicament, for example in the treatment of frontotemporal dementia. | 2022-08-18 |
20220259284 | CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION - The present disclosure provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities. | 2022-08-18 |
20220259285 | CD80 and CD86 Binding Protein Compositions and Uses Thereof - This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. | 2022-08-18 |
20220259286 | CD80 and CD86 Binding Protein Compositions and Uses Thereof - This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. | 2022-08-18 |
20220259287 | SINGLE CHAIN FACTOR VIII MOLECULE - The present invention relates to a recombinant Factor VIII protein comprising, in a single chain, a heavy chain portion comprising an A1 and an A2 domain and a light chain portion comprising an A3, C1 and C2 domain of Factor VIII, wherein the B-domain is partially deleted in two deletions, the first leading to the presence of a defined processing sequence cleavable by thrombin, and the second leading to absence of the furin cleavage recognition site at position R1664-R1667. An internal fragment of the B-domain is maintained Nucleic acids encoding said protein, host cells and methods of preparing the protein are also provided, as well as a pharmaceutical composition comprising the protein, nucleic acid or host cell, which may be used for treatment of hemophilia A. | 2022-08-18 |
20220259288 | HUMAN APOB100 EPITOPES, METHODS AND USES FOR MODULATING INFLAMMATORY RESPONSES, AND TREATING ADVERSE CARDIOVASCULAR EVENTS, DISEASE AND ATHEROSCLEROSIS - Provided herein are composition comprising novel epitopes of ApoB100, as well as sub-sequences, portions and modifications thereof, and uses thereof for treating adverse cardiovascular events, cardiovascular disease, atherosclerosis and certain liver disorders. | 2022-08-18 |
20220259289 | CD137 BINDING FIBRONECTIN TYPE III DOMAINS - FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications. | 2022-08-18 |
20220259290 | INNOVATIVE PRODUCTION TECHNIQUE FOR ANTIBODY-ENZYME - A method for producing a κ light chain antibody having enzyme activity or improved enzyme activity includes modifying a polynucleotide that encodes a κ light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is a proline residue, to delete or substitute the proline residue and to obtain a polynucleotide that encodes a κ light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue, and expressing a κ light chain antibody having enzyme activity in an intracellular or extracellular expression system by using an expression vector including the polynucleotide that encodes a κ light chain antibody obtained after modification. | 2022-08-18 |
20220259291 | ANTIBODY PURIFICATION METHODS AND COMPOSITIONS THEREOF - Methods of purifying a humanized α4β7 antibody, such as vedolizumab, produced in a mammalian cell culture are described herein, as are compositions resulting from said purification processes. | 2022-08-18 |
20220259292 | A METHOD OF TREATING HBV INFECTION BY USING ANTI-PRE-S1 HBV ANTIBODIES - A method for treating HBV infection in a subject, comprising administering to the subject an anti-pre-S1 antibody or a fragment thereof at a dose of about 0.1 mg/kg to about 80 mg/kg. Also relates to an anti-pre-S1 antibody or a fragment thereof for use in treating HBV infection. | 2022-08-18 |
20220259293 | ANTIBODIES AGAINST MICROORGANISMS AND USES THEREOF - Described herein are methods and antibodies useful for reducing, eliminating, or preventing infection with a bacterial population in domestic animals or humans. Also described herein are antigens useful for targeting by heavy chain antibodies and V | 2022-08-18 |
20220259294 | BINDING MOIETIES FOR BIOFILM REMEDIATION - Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described. | 2022-08-18 |
20220259295 | Method useful in tolerance induction therapy and kits therefore - Protease nexin-1 (PN-1) is a member of the serine protease inhibitor (Serpin)-family, with thrombin as its main target. Current polyclonal and monoclonal antibodies against PN-1 frequently cross-react with Plasminogen activator inhibitor-1 (PAI-1), a structurally and functionally homologous Serpin. Herein the inventors develop inhibitory single-domain antibodies (VHHs) showing specific binding to both human (hPN-1) and murine (mPN-1) PN-1 and which de not cross-react with PAI-1. Importantly, all VHHs could block PN-1 activity in plasma as well as PN-1 released from activated platelets, one of the main sources of PN-1 during hemostasis. Thus, the present invention relates to anti-protease nexin-1 (PN-1) conformational single domain antibodies and uses thereof in particular in the therapeutic field for the treatment of haemorrhagic diseases. | 2022-08-18 |
20220259296 | COMPLEMENT C3 ANTIGEN BINDING PROTEINS - Antigen-binding proteins with specificity to complement C3 and C3b are provided. Methods of treating complement C3-mediated diseases and disorders, methods of inhibiting the activity of the complement Classical pathway (CP), Lectin pathway (LP), and/or Alternative pathway (AP), and methods of inhibiting the activity of choroidal-localized complement C3 are also provided. | 2022-08-18 |
20220259297 | COMPOSITIONS AND METHOD FOR TREATING KIDNEY DISEASE - In some aspects, the disclosure relates to activin and/or GDF antagonists and methods of using activin and/or GDF antagonists to treat, prevent, or reduce the progression rate and/or severity of kidney disease, particularly treating, preventing or reducing the progression rate and/or severity of one or more kidney disease-associated complications. | 2022-08-18 |
20220259298 | Neutralizing Antibody for Tooth Regeneration Treatment Targeting USAG-1 Molecule - Provided are: an antibody which specifically binds to and neutralizes USAG-1 or an antigen-binding fragment thereof; and a pharmaceutical composition containing the antibody or the antigen-binding fragment. | 2022-08-18 |
20220259299 | ANTI-IL-27 ANTIBODIES AND USES THEREOF - The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample. | 2022-08-18 |
20220259300 | VACCINE COMPOSITION COMPRISING A MUTANT OF HUMAN INTERLEUKIN-15 - Vaccine composition containing a mutant of the human Interleukin-15 (IL-15). The use of said mutant polypeptide of human IL-15 to manufacture a medicament for the active immunotherapy of diseases associated with IL-15 overexpression, including some autoimmune diseases and hematological malignancies. Administration to an individual that needs it of a therapeutically effective amount of the vaccine, that comprises the mutant polypeptide of the human IL-15 of the invention, constitutes a method for the therapy of IL-15 over-expressing related diseases. | 2022-08-18 |
20220259301 | METHODS OF TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS - The present disclosure relates to methods of treating Crohn's disease or inducing remission of Crohn's disease in a subject. The present disclosure also relates to methods of treating ulcerative colitis or inducing remission of ulcerative colitis in a subject. | 2022-08-18 |
20220259302 | METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF LYSOSOMAL FUNCTION AND TREATMENT OF NEURODEGENERATIVE DISEASE - Disclosed are methods of reducing age-dependent lysosome impairment and/or treating an age related neurodegenerative disease, fibrotic disease, or rheumatological disease in a subject comprising administering to the subject a therapeutic agent; wherein the therapeutic agent inhibits nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase (NOX) or downstream NOX effector. | 2022-08-18 |
20220259303 | ANTI-CLD18A2 NANOBODY AND USE THEREOF - The present disclosure relates to the field of biology, in particular, to an anti-CLD18A2 VHH. The present disclosure provides an anti-CLD18A2 VHH. A complementarity determining region (CDR) of the anti-CLD18A2 VHH includes CDR1-CDR3 having amino acid sequences as shown below: CDR1 having an amino acid sequence represented by one of SEQ ID NO. 4-11, CDR2 having an amino acid sequence represented by one of SEQ ID NO. 19-26, and CDR3 having an amino acid sequence represented by one of SEQ ID NO.33-39. The anti-CLD18A2 VHH of the present disclosure can specifically bind to the epitope on CLD18A2, and the corresponding fusion protein thereof has good specificity and affinity for CLD18A2, and has a noticeable tumor suppression effect. | 2022-08-18 |
20220259304 | THERAPEUTIC MUSK ANTIBODIES - The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies. | 2022-08-18 |
20220259305 | METHODS FOR TREATMENT OF REFRACTORY GENERALIZED MYASTHENIA GRAVIS WITH ECULIZUMAB - The disclosure provides methods of treating refractory myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody. In certain embodiments, the patient achieves and maintains the status of improved or MM according to the MGFA Post-Intervention Status. | 2022-08-18 |
20220259306 | NKG2A ANTIBODY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - Provided are an antibody targeting NKG2A, a preparation method therefor and use thereof. Specifically, provided is a new mouse or humanized monoclonal antibody targeting NKG2A, and a method for preparing the monoclonal antibody. The monoclonal antibody can bind to an NKG2A antigen with high specificity, and has high affinity and significant activities such as anti-tumor activity. | 2022-08-18 |
20220259307 | CD33 ANTIBODIES AND METHODS OF USING THE SAME TO TREAT CANCER - The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CDS 3 protein. The antibodies of the present technology are useful in methods for detecting and treating Alzheimer's disease or a CDS 3-associated cancer in a subject in need thereof. | 2022-08-18 |
20220259308 | FCRN ANTIBODIES AND METHODS OF USE THEREOF - Methods for intravenous dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject. | 2022-08-18 |
20220259309 | ANTIBODY COMBINATIONS FOR TREATMENT OF CANCER IN SPECIFIC PATIENTS - Described is the combined use of a first antibody molecule that specifically binds FcyRIIb via its Fab region and that binds an Fey receptor via its Fc region, and a second antibody molecule that specifically binds PD-1 and that binds at least one Fey receptor via its Fc region, in the treatment of cancer in a patient having tumor infiltrating T lymphocytes with a medium or high PD-1 expression, as well as pharmaceutical compositions and kits comprising these two antibody molecules, and methods of treating cancer using these two antibodies. Described is also a diagnostic test for identification of patients benefitting from the treatment described herein. | 2022-08-18 |
20220259310 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF - The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided. | 2022-08-18 |
20220259311 | ANTI-CD47 COMBINATION THERAPY - The present invention provides a combination therapy for treating a tumor in a subject. The combination comprises two elements. The first is a polypeptide construct comprising an attenuated Type I interferon (IFN) linked to an antibody which binds to a cell surface-associated antigen expressed on the tumour cell and comprising a functional Fc region. The second is a CD47 antagonist which inhibits the interaction CD47 with the SIRPα receptor. | 2022-08-18 |
20220259312 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY - Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce. | 2022-08-18 |
20220259313 | ADMINISTRATION OF A PD-1 INHIBITOR FOR FOR TREATING SKIN CANCER - The disclosure relates to methods for treating or inhibiting the growth of a tumor in a patient with a skin cancer, including administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an antibody or antigen-binding fragment thereof that specifically binds PD-1, PD-L1, and/or PD-L2). In certain embodiments, the method includes administering a PD-1 inhibitor as adjuvant treatment after the patient has completed surgery and optionally radiation therapy for skin cancer, such as CSCC, and is at high risk for disease recurrence. In certain embodiments, the method includes administering a PD-1 inhibitor as neoadjuvant treatment before planned surgery for skin cancer. In certain embodiments, the method includes administering a PD-1 inhibitor as neoadjuvant treatment before planned surgery for skin cancer and subsequently administering to the patient a PD-1 inhibitor as adjuvant therapy after such surgery. | 2022-08-18 |
20220259314 | BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3 - The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same. | 2022-08-18 |
20220259315 | Immunological Reagents - This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction. | 2022-08-18 |
20220259316 | Multiple-Variable Dosage Regimen for the Treatment of Cancers with High Expression of EGFR - The present disclosure relates to a multiple-variable dosage regimen for the treatment of cancers with high expression of EGFR. Particularly, the present disclosure relates to a multiple-variable dosage regimen for treating cancers with high EGFR expression in a subject in need, comprising: administering a first dose of anti-EGFR antibody or antigen-binding fragment thereof to said subject in a first treatment cycle; and subsequently administering a second dose of anti-EGFR antibody or antigen-binding fragment thereof to said subject during the second treatment cycle. The regimen described in the present disclosure realizes favorable effects to cancer treatment. | 2022-08-18 |
20220259317 | FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME - An embodiment of the invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed. | 2022-08-18 |
20220259318 | ANTIBODIES BINDING TO GPRC5D - The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease. | 2022-08-18 |
20220259319 | METHODS AND COMPOSITIONS RELATING TO ADENOSINE RECEPTORS - Provided herein are methods and compositions relating to adenosine A2A receptor libraries having nucleic acids encoding for a scaffold comprising an adenosine A2A binding domain. adenosine A2A receptor libraries described herein encode for immunoglobulins such as antibodies. | 2022-08-18 |
20220259320 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF - Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC). | 2022-08-18 |
20220259321 | COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS - The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy. | 2022-08-18 |
20220259322 | ANTI-GRP78 ANTIBODIES AND METHOD OF USE THEREOF - The present invention is directed towards isolated antibodies that bind to GRP78. Specifically, compositions comprising anti-GRP78 antigen binding proteins useful in recognition of cancer or tumor cells. Moreover, in some aspects, the anti-GRP78 antigen binding proteins are useful for tumor/cancer-specific delivery of drugs and therapies. In another aspect, the disclosed antigen binding proteins are useful for enhancing radiotherapy in a subject having or suspected of having cancer or a tumor where the antigen binding protein is conjugated to a payload, for example, a therapeutic agent, an imaging agent, or a combination thereof. | 2022-08-18 |
20220259323 | Glycan-Interacting Compounds and Methods of Use - The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included. | 2022-08-18 |
20220259324 | ANTI-NME ANTIBODY AND METHOD OF TREATING CANCER OR CANCER METASTASIS - The present application discloses anti-NME antibodies and their use in treating or preventing diseases. | 2022-08-18 |
20220259325 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders - In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent. | 2022-08-18 |
20220259326 | ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER - The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. | 2022-08-18 |
20220259327 | ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER - The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. | 2022-08-18 |
20220259328 | BISPECIFIC ANTIBODY BINDING TO CD40 AND FAP - An object of the present invention is to provide a bispecific antibody, which binds to CD40 and FAP and exhibits a strong CD40 agonistic activity in a FAP dependent manner or a bispecific antibody fragment thereof, and the like. The present invention relates to a bispecific antibody, which is a bispecific antibody containing an IgG portion including a first antigen binding domain and also containing a second antigen binding domain, and binding to human CD40 and human FAP, wherein the C terminus of a heavy chain of the IgG portion binds to the second antigen binding domain either directly or via a linker, or a bispecific antibody fragment thereof, and the like. | 2022-08-18 |
20220259329 | BISPECIFIC BINDING CONSTRUCTS - New formats of bispecific binding constructs are described, as well as their methods of making. Additionally, uses in therapeutic indications are also described. | 2022-08-18 |
20220259330 | TETRAVALENT BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF - Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases. | 2022-08-18 |
20220259331 | RADIX PUERARIAE POLYSACCHARIDE, AND PREPARATION METHOD AND USE THEREOF - A preparation of a homogeneous polysaccharide from a | 2022-08-18 |
20220259332 | PARTICLE-BASED METHOD FOR DEFINING A GUT MICROBIOTA IN HUMANS OR OTHER ANIMAL SPECIES - The present disclosure provides retrievable artificial food particles comprising one or more compound of interest, and methods of using the artificial food particles. The methods disclosed herein can be used to characterize the composition and/or functional state of a subjects gut microbiota. Other aspects of the compositions and methods are described in further detail. | 2022-08-18 |
20220259333 | Modified Conjugated Diene-Based Polymer and Rubber Composition Including the Same - A modified conjugated diene-based polymer and a rubber composition including the same are disclosed herein. The modified conjugated diene-based polymer has excellent processability and good tensile strength and viscoelasticity. In some embodiments, a modified conjugated diene-based polymer includes a derived unit from a modifier, the modifier including three or more alkoxy groups bonded to silicon; a non-functional chain forming a silicon-carbon bond at one side of the derived unit from a modifier and including a repeating unit derived from a conjugated diene-based monomer; and a functional chain forming a silicon-carbon bond at the other side of the derived unit from a modifier and including two or more derived units from an N-functional group-containing monomer. | 2022-08-18 |
20220259334 | METHOD FOR OBTAINING FUNCTIONALIZED POLYMERIC SURFACES WITH PHOTOSENSITIZERS, FUNCTIONALIZED POLYMERIC MATERIAL AND USE THEREOF - The present invention describes methods for obtaining functionalized polymeric surfaces (MPn-PSm) from polymers or copolymers with appropriate functionalizations (X), which can be a halogen of a leaving group, such as polyvinyl chloride (MP1) and (chloromethyl)polystyrene-Merrifield (MP2), and curcumin photosensitizers (PS1), meso-tetra(aryl)porphyrins, chlorins or bacteriochlorins halogenated and functionalized with nucleophilic groups (PS2), in particular including P2 of the type meso-imidazoyl-porphyrins, chlorins or bacteriochlorins (PS3). The structures of all the photosensitizers in the present application incorporate a functional group (Y), which is a OH, SH or NH | 2022-08-18 |
20220259335 | METHOD FOR MANUFACTURING POLYMER - Object: To provide a method for manufacturing a polymer, which is a method for forming a polymer having a homogeneous copolymer composition and a narrow molecular weight distribution. | 2022-08-18 |
20220259336 | OLEFIN POLYMERIZATION CATALYSTS BEARING A THIAZOLE OR IMIDAZOLE - Processes of polymerizing olefin monomers using catalyst systems comprising a procatalyst having a structure according to Formula (I). | 2022-08-18 |
20220259337 | METHOD FOR PRODUCING AQUEOUS FLUOROPOLYMER DISPERSION, DRAINAGE TREATMENT METHOD, AND AQUEOUS FLUOROPOLYMER DISPERSION - A method for producing a fluoropolymer aqueous dispersion, including a step A of performing ultrafiltration, microfiltration, or dialysis membrane treatment, or a combination thereof on a pretreatment aqueous dispersion containing a fluoropolymer obtained by polymerization in the presence of a polymer (I) including a polymerized unit (I) derived from a monomer represented by the following general formula (I), with the proviso that the fluoropolymer is other than the polymer (I): | 2022-08-18 |
20220259338 | IMAGE FORMING DEVICE AND IMAGE FORMING METHOD - An image forming device includes a first discharging device configured to discharge a first active energy curing composition (1) containing a first (meth)acrylic amide compound (A) having a (meth)acrylic group and a first polymerization initiator (C) to a medium, a first exposing device configured to expose the first active energy curing composition (1) applied to the medium to first active energy, and a second discharging device configured to discharge an ink (2) containing a coloring material, a water-soluble organic solvent, and water to the first active energy curing composition (1) exposed to the first active energy. | 2022-08-18 |
20220259339 | POLYPROPYLENE FILM WITH IMPROVED SLIP PERFORMANCE - The invention is related to film comprising a polypropylene composition showing improved coefficiency of friction as well as optical properties. | 2022-08-18 |
20220259340 | COPOLYMER OF ETHYLENE AND ION PAIR COMPOUND - The invention relates to an ehtylene copolymer obtained by copolymerizing ethylene and an ion pair compound consisting of a cation of formula (I) and an anion selected from formulas (II), (III), (IV) and (V), wherein (I) where R1=H or C1-C10 alkyl; X=O or NH; R2=C1-C40 alkyl; R3, R4=H or C1-C10 alkyl which can be connected through a cyclic structure, R5=H or C1-C20, (II) (III) (IV) (V) where R6, R7, R9=H or C1-C10 alkyl; R8, R10=C1-C40 alkyl; Y, V, W=O or NH; n=1 to 20; Z=—SO | 2022-08-18 |
20220259341 | Ethylene-Based Polymer Composition with Branching - The present disclosure provides an ethylene-based polymer. The ethylene-based polymer is formed from reacting, under polymerization conditions, ethylene monomer and bisallyl maleate (“BAIIM”). The present ethylene-based polymer with ethylene monomer and bisallyl maleate branching agent is interchangeably referred to as “BAIIM-PE.” | 2022-08-18 |
20220259342 | HIGH TEMPERATURE SOLUTION PROCESS FOR THE COPOLYMERIZATION OF ALPHA-OLEFINS - A process for the solution polymerization of a polymer from an α-olefin monomer and one or more α-olefin comonomers in the presence of a catalyst, the process having a catalyst performance index (CPI) not higher than 15, wherein the catalyst performance index is defined according to equation (I): | 2022-08-18 |
20220259343 | POLYMERS FOR CALORIC APPLICATIONS - Various embodiments disclosed relate to unsaturated polymers that exhibit electrocaloric properties. The polymers can be useful as heat transfer materials in heating and cooling applications. | 2022-08-18 |
20220259344 | USE OF VINYL ACETATE COPOLYMERS AS A LOW-PROFILE ADDITIVE - A low profile additive includes vinyl acetate-isopropenyl acetate copolymers. The vinyl acetate-isopropenyl acetate copolymers are based on from 2 to 98% by weight of vinyl acetate, from 2 to 98% by weight of isopropenyl acetate and optionally one or more further ethylenically unsaturated monomers, in each case based on the total weight of the vinyl acetate-isopropenyl acetate copolymers. | 2022-08-18 |
20220259345 | ACRYLIC RUBBER BALE EXCELLENT IN STORAGE STABILITY AND PROCESSABILITY - Acrylic rubber bale excellent in storage stability and processability, a method for producing the same, a rubber mixture obtained by mixing the acrylic rubber bale, and a cross-linked product of the rubber mixture are provided. The acrylic rubber bale includes an acrylic rubber having a reactive group and a weight average molecular weight (Mw) of 100,000 to 5,000,000, wherein an amount of gel insoluble in methyl ethyl ketone is 60% by weight or less, and a specific gravity is 0.8 or more. | 2022-08-18 |
20220259346 | AQUEOUS COATING COMPOSITION - The invention concerns a composition for preparing a coating, such as a paint or a varnish, comprising an acrylic acid copolymer thickener, a polymer binder chosen from a vinyl acetate homopolymer, a vinyl acetate copolymer, a vinyl versatate homopolymer, a vinyl versatate copolymer and combinations thereof, and water. The invention also concerns the use of the acrylic acid copolymer in an aqueous coating composition comprising such a polymer binder in order to improve the stability of same during storage. | 2022-08-18 |
20220259347 | ACRYLIC RUBBER EXCELLENT IN WATER RESISTANCE - An acrylic rubber excellent in water resistance and a method for producing the same are provided. An acrylic rubber composed of: 70 to 99.9 wt % of a bonding unit derived from (meth) acrylic acid ester; 0.1 to 10 wt % of a bonding unit derived from a cross-linkable monomer; and if necessary, 0 to 20 wt % of a bonding unit derived from another monomer, wherein the ash content is 0.5 wt % or less, the total amount of magnesium and phosphorus in the ash is 30 wt % or more, a ratio of the magnesium to the phosphorus ([Mg]/[P]) by weight is 0.4 to 2.5, and Mooney viscosity (ML1+4, 100° C.) of the rubber is 10 to 150 is particularly excellent in water resistance, and a rubber cross-linked product using the same is also excellent in physical properties. | 2022-08-18 |
20220259348 | ACRYLIC RUBBER BALE EXCELLENT IN STRENGTH PROPERTIES AND PROCESSABILITY - An acrylic rubber bale excellent in strength properties and processability, a method for producing the same, a rubber mixture containing the acrylic rubber bale, a method for producing the same, and a rubber cross-linked product of the same. The acrylic rubber bale includes an acrylic rubber mainly containing a (meth) acrylic acid ester having a weight average molecular weight (Mw) of 1,000,000 to 5,000,000, and a ratio (Mz/Mw) of a Z-average molecular weight (Mz) and a weight average molecular weight (Mw) is 1.3 or more, wherein an amount of gel insoluble in methyl ethyl ketone is 50% by weight or less. | 2022-08-18 |
20220259349 | OPTICAL RESIN AND LIGHTING DEVICE HAVING SAME - A lighting device disclosed in an embodiment of the invention includes a substrate; a light emitting device disposed on the substrate; a resin layer sealing the light emitting device on the substrate; and a diffusion layer or a reflective substrate disposed on the resin layer, wherein the resin layer includes an oligomer, a monomer, and an additive, wherein the monomer includes IBOA (Iso-bornyl Acrylate), two or more dilution monomers and glycidyl methacrylate (GMA), the additive includes a photoinitiator and an amine-based light stabilizer, and in the oligomer and the monomer, the content of glycidyl methacrylate is 10 to 15%, and the resin layer may be a curable transparent resin cured by ultraviolet light. | 2022-08-18 |
20220259350 | CONTAMINANT REMEDIATION WITH FUNCTIONALIZED (METH)ACRYLIC POLYMER OR COPOLYMER MACROPARTICULATES AND SYSTEMS RELATED THERETO - Macroparticulates may be formed through at least partial self-assembly by reacting an epoxide-containing (meth)acrylic polymer or copolymer with a compound bearing a nitrogen nucleophile. An internal cavity may be formed when functionalizing the (meth)acrylic polymer or copolymer in the presence of a hindered amine base. When appropriately functionalized, the macroparticulates may be used to sequester a contaminant from a substance in need of contaminant remediation, such as produced water or flowback water from a wellbore job site. Reclaimed water obtained from the macroparticulates may be utilized to form a treatment fluid. The macroparticulates may be located within a continuous flow line, particularly within a removable cartridge, to promote removal of at least one contaminant from a substance in need of contaminant remediation. The substance in need of contaminant remediation and/or the macroparticulates may be visually or spectroscopically interrogated to determine whether the macroparticulates have become saturated with contaminant. | 2022-08-18 |
20220259351 | FUNCTIONALIZED (METH)ACRYLIC POLYMER OR COPOLYMER MACROPARTICULATES AND METHODS FOR PRODUCTION AND USE THEREOF - Macroparticulates may be formed through at least partial self-assembly by reacting an epoxide-containing (meth)acrylic polymer or copolymer with a compound bearing a nitrogen nucleophile, such as iminodiacetic acid or ethylenediamine. When the epoxide-containing (meth)acrylic polymer or copolymer is formed into a predetermined shape before reaction with the compound bearing the nitrogen nucleophile, a profile of the predetermined shape may be at least partially maintained and undergo expansion in the course of forming the reaction product, thereby producing macroparticulates having a larger volume than the predetermined shape itself. An internal cavity may be formed when generating the macroparticulates in this manner. Optionally, a hexasubstituted benzene or a supramolecular receptor may be adhered to a surface portion of the macroparticulates, either covalently or non-covalently. The compound bearing a nitrogen nucleophile may be further modified to form one or more functionalities capable of binding an analyte. | 2022-08-18 |
20220259352 | Compound for encapsulation film and composition thereof, and film, organic light-emitting device and encapsulation method - A compound for an encapsulation film and a composition thereof, a film, an organic light-emitting device, and an encapsulation method are provided. The compound has the structure shown in formula 1, and the composition comprises the compound, one or more photocurable and thermocurable propenyl compounds, and one or more compounds that produce a free radical and produce an acid under light or heat. The encapsulation film includes the composition as a film of an organic layer. The organic light-emitting device includes the film. The encapsulation method involves encapsulating the organic light-emitting device using the encapsulation film. The composition containing the compound serves as an organic layer. An encapsulation film for the organic light-emitting device is manufactured by repetitively and alternately laminating an inorganic layer and the organic layer. | 2022-08-18 |
20220259353 | THERMORESPONSIVE COPOLYMER, NANOFIBER STRUCTURE COMPRISING THE SAME, AND METHOD FOR PREPARING NANOFIBER STRUCTURE - The present invention relates to a thermoresponsive copolymer, a nanofiber structure comprising the same, and a method for preparing a nanofiber structure, more specifically relates to a thermoresponsive copolymer, which can be applied to various industrial fields since of which the contraction or expansion can be controlled based on a specific lower critical solution temperature and the mechanical strength is a certain level or higher as well as the core-shell structure exhibiting improved hydrophilicity can increase the amount of water absorbed/desorbed, a nanofiber structure comprising the same, and a method for preparing a nanofiber structure. | 2022-08-18 |
20220259354 | PHOTOSENSITIVE POLYMER AND RESIST COMPOSITION HAVING THE SAME - Disclosed are a photosensitive polymer including a repeating unit of Chemical Formula 1 or Chemical Formula 2 derived from a vinyl heteroaromatic compound and a resist composition including the same. | 2022-08-18 |
20220259355 | POLYMERIZABLE COMPOSITION, CYCLOOLEFIN-BASED POLYMER, AND METAL/RESIN COMPOSITE - Provided is a polymerizable composition comprising a cycloolefin-based monomer having a specific structure, a silane coupling agent having at least one hydrocarbon group having a norbornene structure, and a metathesis polymerization catalyst. | 2022-08-18 |
20220259356 | TRACEABLE COMPOSITE POLYMERS AND PREPARATION METHODS THEREOF FOR PROVIDING TRANSPARENCY IN PRODUCTION VALUE CHAINS - The present invention is in the field of polymers comprising identifiable tracers by spectroscopic methods such as XRF, IR, NIR and XRD allowing information to be encoded by the polymers, and in particular polymers for conservation, restoration and retouching in artworks, electronics, coatings, plastics, packaging, 3D printing, rubber, and the like. | 2022-08-18 |
20220259357 | HYBRID FUNCTIONAL FLUOROPOLYMERS - A silane functionalized fluoropolymer-acrylic composition is disclosed. | 2022-08-18 |
20220259358 | Graft Copolymer, Method for Preparing the Same, and Resin Composition Including the Same - Disclosed is a graft copolymer, and a graft copolymer including a rubbery polymer, wherein the rubbery polymer includes a conjugated diene-based monomer unit, and one or more compound units selected from the group consisting of compounds represented by Formula 1, wherein the graft copolymer includes an alkyl (meth)acrylate-based monomer unit and an aromatic vinyl-based monomer unit, the content of the one or more compound units selected from the group consisting of the compounds represented by Formula 1 is from 0.1 wt % to 5.0 wt % with respect to the graft copolymer, the alkyl (meth)acrylate-based monomer unit is crosslinked from a crosslinking agent, and a weight average molecular weight of the aromatic vinyl-based monomer unit is from 20,000 g/mol to 100,000 g/mol. Also disclosed is a method for preparing a graft copolymer and a resin composition including same. | 2022-08-18 |
20220259359 | TRANSPARENT THERMOPLASTIC RESIN COMPOSITION AND ARTICLE MOLDED THEREOF - A transparent thermoplastic resin composition includes: 100 parts by mass of a transparent thermoplastic resin composition composed of 10 to 60 parts by mass of a graft copolymer (A) obtained by graft-copolymerizing a monomer mixture (a) containing at least an aromatic vinyl-based monomer (a1) and a (meth)acrylic acid ester-based monomer (a2) in the presence of a rubbery polymer (r), and 40 to 90 parts by mass of a vinyl-based copolymer (B) obtained by copolymerizing a monomer mixture (b) containing at least an aromatic vinyl-based monomer (b1), a (meth)acrylic acid ester-based monomer (b2), and a vinyl cyanide-based monomer (b3); and 15 ppm or more and 40 ppm or less of a polydimethyl siloxane gum (C) having a weight-average molecular weight of 300,000 or more. | 2022-08-18 |
20220259360 | Omniphobic Compatibilizers for Clear Coatings, Related Articles, and Related Methods - The disclosure generally relates to omniphobic compatibilizers, which include a polymerization reaction product between a first vinyl monomer, optionally a second vinyl crosslinking monomer, and a functionalized omniphobic polymer. The functionalized omniphobic polymer can include two or more vinyl functional groups or at least one free radical initiator functional group such that the reaction product forming the omniphobic compatibilizer can be a vinyl or free-radical polymerization product. The omniphobic compatibilizer can be incorporated into a UV-curable or a non-UV-curable thermoset omniphobic composition. The UV-curable composition can be a crosslinked polymerization reaction product between the omniphobic compatibilizer, a third vinyl monomer, and a fourth polyvinyl crosslinking monomer. The non-UV-curable composition can be a crosslinked polymerization reaction product between the omniphobic compatibilizer, a first thermosetting component, and a second thermosetting component. The thermoset omniphobic composition can be a coating on a substrate in a corresponding coated article. | 2022-08-18 |
20220259361 | RESIN COMPOSITION FOR STEREOLITHOGRAPHY - A resin composition for stereolithography may emit a weak odor, enable easy fabrication of an object, and may be made into a cured product having desirable toughness and water resistance when used for stereolithographical fabrication. A resin composition for stereolithography may include: an α,β-unsaturated double bond group-containing compound (A) having a homopolymer glass transition temperature (Tg) of 40° C. or more, having a plurality of independent aromatic rings, and having no urethane bond; an α,β-unsaturated double bond group-containing compound (B) having a homopolymer glass transition temperature (Tg) of less than 40° C., having a ring structure, and having a normal boiling point of 250° C. or more; and a photopolymerization initiator (C). | 2022-08-18 |
20220259362 | PREPARING METHOD OF SUPERELASTOMER, SUPERELASTOMER PREPARED USING THE SAME, AND MOLDED ARTICLE CONTAINING SUPERELASTOMER - Provided are a preparing method of a superelastomer, a superelastomer prepared using the same, and a molded article containing the superelastomer, and the superelastomer can be used as a biomaterial replacing soft tissues due to excellent strain at break and elastic recovery. | 2022-08-18 |
20220259363 | RESIN COMPOSITION, PREPREG, FILM WITH RESIN, METAL FOIL WITH RESIN, METAL-CLAD LAMINATE, AND WIRING BOARD - An aspect of the present invention is a resin composition containing a first styrene-based block copolymer having a hardness of 20 to 70, a polyphenylene ether compound having at least one of a group represented by the following Formula (1) and a group represented by the following Formula (2) in a molecule, and a curing agent. | 2022-08-18 |
20220259364 | SOLVENT-BASED COMPOSITIONS - Embodiments of the present disclosure are directed towards solvent-based compositions that include a reaction product formed by reacting a polyol and an aminopolycarboxylic compound. | 2022-08-18 |
20220259365 | COMPOSITION AND PROCESS FOR PRODUCING SILYLATED POLYMERS AND USE THEREOF - The invention relates to a composition comprising and to a process for preparing moisture-crosslinking polymers under catalysis by a metal-siloxane-silanol(ate) compound, and to the use of the composition in the CASE sector (coatings, adhesives, sealants and elastomers), especially in the field of adhesives and sealants. | 2022-08-18 |
20220259366 | Aqueous Cationic Polyurethane Dispersions - An aqueous polyurethane resin dispersion, the polyurethane resin having a polyalkylene oxide in a side chain thereof and is obtainable by reacting in an organic solvent, a polyisocyanate with a 1,2 or 1,3 polyether diol and with a polymeric diol selected from the group consisting of polyester diol, polyether diol, polycarbonate diol, polyacrylate diol and polyolefin diol and by adding a cationic surfactant or cationic surfactant precursor to the organic solvent. | 2022-08-18 |